Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 34

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 34
---
10,089 |     | $      | 8,937,852 |     |              | 7,266 |   |     | $      | 1 |     | $          | 53,899,885 |   |     | $            | (2,000,000 | ) |     | $           | (63,185,641 | ) |     | $     |  (2,347,903 | ) |

<div align='center'>12</div>

NOTE 4 – NET LOSS PER SHARE OF COMMON STOCK

The accounting standards
require the presentation of both basic and diluted earnings per share on the face of the statements of operations. The Company’s
basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of shares
of common stock outstanding for the period. If there are dilutive securities, diluted income per share is computed by including common
stock equivalents which includes shares issuable upon the exercise of stock options into shares of common stock, exercise of preferred
warrants into shares of preferred stock, and conversion of preferred stock into shares of common stock, net of any shares assumed to have
been purchased with the proceeds, using the treasury stock method. In periods for which the Company reports a net loss, the common stock
equivalents are not included, as they would be anti-dilutive.

The following table summarizes
the number of shares of Common Stock issuable upon conversion or exercise, as applicable, of convertible securities, stock options, and
warrants that were not included in the calculation of diluted net loss per share because such shares are anti-dilutive:

|                                                                                           |     | 2025       |        For the 
 three and nine 
   months ended 
  September 30, |     | 2024       |       For the 
  three months 
         ended 
 September 30, 
          2024 
   and for the 
   period from 
  February 14, 
          2024 
       through 
 September 30, |     | 2024         |      For the 
  period from 
   January 1, 
         2024 
      through 
 February 14, |
|:------------------------------------------------------------------------------------------|:----|:-----------|---------------:|:----|:-----------|--------------:|:----|:-------------|-------------:|
|                                                                                           |     | -Successor |                |     | -Successor |               |     | -Pre